Trial reportHypertension (Dallas, Tex. : 1979)2019
Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia: INSPIRE.
Trial report in Hypertension (Dallas, Tex. : 1979), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Placental growth factor (PLGF)-based testing to help diagnose suspected pre-eclampsia: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2026Pooled it
- Placental Growth Factor (PlGF)- Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment.Ontario health technology assessment series · 2023Pooled it
- sFlt-1/PlGF ratio use does not reduce hospitalisation duration in suspected preeclampsia: the PRECOG study, a multicentre randomised trial.Scientific reports · 2025Trial
- Repeat Placental Growth Factor-Based Testing in Women With Suspected Preterm Preeclampsia: A Stratified Analysis of the PARROT-2 Trial.Hypertension (Dallas, Tex. : 1979) · 2024Trial
- The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial.BMC pregnancy and childbirth · 2022Trial
- Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland).BMJ (Clinical research ed.) · 2021Trial
- Placental growth factor measurements in the assessment of women with suspected Preeclampsia: A stratified analysis of the PARROT trial.Pregnancy hypertension · 2021Trial
- Hypertensive disorders of pregnancy and women's health throughout the life course: an update review 2025-2026.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations.Journal of the American Society of Nephrology : JASN · 2026Review
- Article
- Obstetric History Versus Biomarkers: Hypertension Risk Up to 15 Years Postpartum.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Evaluation of analytical performance of the Revvity sFlt-1 and PlGF methods for the assessment of preeclampsia.British journal of biomedical science · 2026Article
- Urinary Congophilia in Pre-Eclampsia: A Potential Diagnostic Biomarker.Journal of pregnancy · 2026Review
- Comparative evaluation of the quality, reliability, and readability of five large language model responses to frequently asked questions on gestational hypertension.Frontiers in public health · 2026Article
- The Role of Angiogenetic Factors in Preeclampsia.International journal of molecular sciences · 2025Review
- Uterine artery Doppler at 11-14 weeks of gestation in the prediction of preeclampsia: An observational study.World journal of radiology · 2025Article
- Novel biomarkers for preeclampsia: Promises and pitfalls.Current opinion in obstetrics & gynecology · 2025Review
- Article
- Kidney disease and reproductive health.Nature reviews. Nephrology · 2025Review
- Preeclampsia: Etiology, Pathophysiology, Risk Factors, Impact and Prevention: A Narrative Review.Iranian journal of public health · 2024Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ratio of maternal serum sFlt-1 (soluble fms-like tyrosine kinase 1) to PlGF (placental growth factor) has been used retrospectively to rule out the occurrence of preeclampsia, a pregnancy hypertensive disorder, within 7 days in women presenting with clinical suspicion of preeclampsia. A prospective, interventional, parallel-group, randomized clinical trial evaluated the use of sFlt-1/PlGF ratio in women presenting with suspected preeclampsia. Women were assigned to reveal (sFlt-1/PlGF result known to clinicians) or nonreveal (result unknown) arms. A ratio cutoff of 38 was used to define low (≤38) and elevated risk (>38) of developing the condition in the subsequent week. The primary end point was hospitalization within 24 hours of the test. Secondary end points were development of preeclampsia and other adverse maternal-fetal outcomes. We recruited 370 women (186 reveal versus 184 nonreveal). Preeclampsia occurred in 85 women (23%). The number of admissions was not significantly different between groups (n=48 nonreveal versus n=60 reveal;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.